布地奈德联合异丙托溴铵治疗小儿毛细支气管炎

Budesonide Combined With Ipratropium Bromide for Children With Bronchiolitis

目的探讨布地奈德联合复方异丙托溴铵治疗毛细支气管炎的临床效果。方法选取2017年10月—2019年10月医院收治的78例毛细支气管炎患儿,按随机数字表法分为两组,各39例。对照组予以常规治疗,观察组加用布地奈德联合复方异丙托溴铵治疗。两组均于用药7 d后比较炎症因子水平、临床症状消失时间及不良反应。结果观察组治疗后超敏C反应蛋白、白介素-8、降钙素原水平为(0.53±0.11)mg/dL、(40.55±9.42)pg/L、(0.42±0.15)ng/mL,均低于对照组,差异有统计学意义(P<0.05);观察组气喘、肺部啰音、咳嗽及发热消失时间为(2.38±0.63)d、(5.14±1.13)d、(3.27±0.95)d、(18.64±2.87)h,均短于对照组,差异有统计学意义(P<0.05);两组均未出现严重不良反应。结论布地奈德联合复方异丙托溴铵可降低毛细支气管患儿炎症因子水平,加快临床症状消失,安全可靠。

Objective To investigate the clinical effect of budesonide combined with compound ipratropium bromide in the treatment of bronchiolitis.Methods From October 2017 to October 2019,78 children with bronchiolitis admitted to our hospital were randomly divided into two groups,39 cases in each group.The control group was treated with routine therapy,the observation group was treated with budesonide combined with compound ipratropium bromide.The level of inflammatory factors,the time of clinical symptoms disappearance and adverse reactions were compared between the two groups after 7 days.Results after treatment,the levels of CRP,IL-8 and calcitonin in the observation group were(0.53±0.11)mg/dL,(40.55±9.42)pg/L,(0.42±0.15)ng/mL,which were lower than those in the control group(P<0.05);the disappearance time of asthma,lung rale,cough and fever in the observation group was(2.38±0.63)d,(5.14±1.13)d,(3.27±0.95)d,(18.64±287)h,shorter than the control group,the difference was statistically significant(P<0.05);no serious adverse reactions occurred in both groups.Conclusion budesonide combined with ipratropium bromide can reduce the level of inflammatory factors in children with bronchiolitis,accelerate the disappearance of clinical symptoms,safe and reliable.